Cargando…
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer
We recently discovered that coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS mutant lung adenocarcinoma. Nevertheless, the evident toxicity restricts the use of wild-type (WT)-CVB3 for cancer therapy. The current study aims to engineer the CVB3 to decrease its toxicity and to extend...
Autores principales: | Liu, Huitao, Xue, Yuan Chao, Deng, Haoyu, Mohamud, Yasir, Ng, Chen Seng, Chu, Axel, Lim, Chinten James, Lockwood, William W., Jia, William W.G., Luo, Honglin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036525/ https://www.ncbi.nlm.nih.gov/pubmed/32123721 http://dx.doi.org/10.1016/j.omto.2020.01.002 |
Ejemplares similares
-
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer
por: Liu, Huitao, et al.
Publicado: (2021) -
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
por: Deng, Haoyu, et al.
Publicado: (2019) -
Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3
por: Liu, Huitao, et al.
Publicado: (2022) -
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
por: Liu, Huitao, et al.
Publicado: (2021) -
Coxsackievirus B3 targets TFEB to disrupt lysosomal function
por: Mohamud, Yasir, et al.
Publicado: (2021)